EZH2 and prostate carcinoma: Though downregulation and loss-of-function mutations suggest tumor suppressive activity of EZH2 in some cancers, evidence to demonstrate that EZH2 with gain-of-function mutations act as oncogene in numerous others, such as prostate cancer, breast cancer and BC37.